Pharma BD Deal Intelligence

Eli Lilly and Company / Sigilon Therapeutics Inc.

2018 · Licensing/Option · $1.8B · Complete

Announcement Sentiment

88

Strongly positive

Outcome Score

31

Underwhelmed — fell short of the thesis.

Lilly licensed Sigilon's Shielded Living Therapeutics platform for Type 1 diabetes cell therapy, paying $63M upfront with up to $1.7B in milestones.

Key facts

Announced Oct 17, 2018
Deal value $1.8B
Deal type Licensing/Option
Therapeutic area Cardiovascular, Gene Therapy, Metabolic
Indications Type 1 diabetes
Key assets Encapsulated cell therapy (SIG-002)
Mechanism Encapsulated cell therapy (Afibromer material)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals